Chardan Capital Issues Pessimistic Forecast for Senti Biosciences (NASDAQ:SNTI) Stock Price

Senti Biosciences (NASDAQ:SNTI) had its price target cut by Chardan Capital from $13.00 to $11.00 in a research note issued on Monday,Benzinga reports. The brokerage currently has a “buy” rating on the stock.

SNTI has been the topic of a number of other reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Senti Biosciences in a research note on Thursday, January 22nd. Wall Street Zen upgraded shares of Senti Biosciences from a “strong sell” rating to a “hold” rating in a research note on Saturday. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $8.50.

Senti Biosciences Price Performance

NASDAQ SNTI opened at $0.81 on Monday. The business’s fifty day moving average is $0.93 and its 200-day moving average is $1.37. The stock has a market capitalization of $25.29 million, a price-to-earnings ratio of -0.25 and a beta of 2.12. Senti Biosciences has a one year low of $0.77 and a one year high of $5.10.

Senti Biosciences (NASDAQ:SNTI) last posted its quarterly earnings results on Friday, March 27th. The company reported ($0.53) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.10). The company had revenue of $0.02 million for the quarter, compared to the consensus estimate of $1.00 million. Research analysts expect that Senti Biosciences will post -14.54 EPS for the current fiscal year.

Hedge Funds Weigh In On Senti Biosciences

Several hedge funds have recently made changes to their positions in the stock. Armistice Capital LLC purchased a new position in Senti Biosciences during the 2nd quarter valued at about $1,883,000. Geode Capital Management LLC lifted its holdings in shares of Senti Biosciences by 395.6% in the second quarter. Geode Capital Management LLC now owns 147,314 shares of the company’s stock worth $311,000 after buying an additional 117,588 shares in the last quarter. Citadel Advisors LLC bought a new position in shares of Senti Biosciences in the third quarter valued at approximately $117,000. Virtu Financial LLC bought a new position in shares of Senti Biosciences in the fourth quarter valued at approximately $46,000. Finally, Jane Street Group LLC purchased a new position in Senti Biosciences during the fourth quarter valued at approximately $40,000. 25.70% of the stock is currently owned by hedge funds and other institutional investors.

About Senti Biosciences

Senti Biosciences (NASDAQ:SNTI) is a clinical-stage synthetic biology company focused on engineering next-generation cell therapies. The company’s platform leverages modular genetic circuits to sense disease signals and precisely control cellular functions, with the goal of improving safety and efficacy in oncology and immune-mediated diseases.

Senti’s core technologies include its SENTINEL circuit platform and SNIP receptor system, which enable programmable sensing of molecular cues and context-dependent payload release.